Healthcare giants in the FTSE 100 index will also be in the spotlight next week. GSK and AstraZeneca will publish their ...

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Chugai Pharm signs collaboration agreement with GSK's Global Health Unit for development of anti-dengue virus antibody: Tokyo Friday, January 31, 2025, 09:00 Hrs [IST] Chugai Phar ...

Sheryl Lee Ralph exclusively told Us Weekly she is ready to reunite with Denzel Washington for an 'adult rom-com' ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

Shares of GSK PLC GSK inched up 0.94% to £14.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,557.81. GSK ...